NCT03779620View on ClinicalTrials.gov

Valvosoft First-In-Man Study in Severe Symptomatic Aortic Stenosis

NACompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

March 13, 2019

Primary Completion Date

January 15, 2022

Study Completion Date

September 27, 2023

Conditions
Aortic Valve Stenosis
Interventions
DEVICE

Ultrasound treatment of Calcified aortic valve

Ultrasound treatment of calcified aortic valve causing symptomatic aortic valve stenosis in patients who are not eligible for valve replacement

Trial Locations (2)

75015

Hôpital Européen Georges Pompidou, Paris

4818CK

Amphia Hospital, Breda

Sponsors

Lead Sponsor

Cardiawave SA
All Listed Sponsors
lead

Cardiawave SA

INDUSTRY

NCT03779620 - Valvosoft First-In-Man Study in Severe Symptomatic Aortic Stenosis | Biotech Hunter | Biotech Hunter